Regenxbio (RGNX) expects its balance in cash, cash equivalents and marketable securities of $278.6M as of September 30, 2024 to fund its operations into 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX: